Wisconsin Capital Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 340.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,015 shares of the company’s stock after purchasing an additional 12,375 shares during the quarter. Wisconsin Capital Management LLC’s holdings in Johnson & Johnson were worth $2,231,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of JNJ. Crawford Investment Counsel Inc. grew its stake in Johnson & Johnson by 0.9% during the second quarter. Crawford Investment Counsel Inc. now owns 562,012 shares of the company’s stock worth $78,277,000 after buying an additional 5,018 shares in the last quarter. Allen Investment Management LLC lifted its holdings in shares of Johnson & Johnson by 5.2% during the 2nd quarter. Allen Investment Management LLC now owns 171,168 shares of the company’s stock worth $23,840,000 after acquiring an additional 8,475 shares during the period. MACRO Consulting Group boosted its position in shares of Johnson & Johnson by 4.2% during the 2nd quarter. MACRO Consulting Group now owns 11,508 shares of the company’s stock worth $1,608,000 after acquiring an additional 466 shares in the last quarter. Weil Company Inc. increased its stake in Johnson & Johnson by 4.0% in the second quarter. Weil Company Inc. now owns 12,206 shares of the company’s stock valued at $1,700,000 after acquiring an additional 466 shares during the last quarter. Finally, Cidel Asset Management Inc. raised its position in Johnson & Johnson by 1.5% during the second quarter. Cidel Asset Management Inc. now owns 208,894 shares of the company’s stock valued at $29,095,000 after purchasing an additional 2,986 shares in the last quarter. Institutional investors and hedge funds own 72.12% of the company’s stock.
A number of brokerages have weighed in on JNJ. Bank of America reaffirmed a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 16th. Raymond James reduced their price objective on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Morgan Stanley reissued an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target on the stock. in a report on Thursday, July 18th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $150.60.
Shares of Johnson & Johnson stock traded up $1.33 on Wednesday, hitting $130.88. The stock had a trading volume of 2,304,302 shares, compared to its average volume of 7,544,466. The stock has a 50 day moving average of $130.07 and a 200 day moving average of $135.99. The firm has a market capitalization of $335.04 billion, a P/E ratio of 16.00, a PEG ratio of 2.15 and a beta of 0.68. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same period in the previous year, the firm posted $2.10 EPS. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a $0.95 dividend. The ex-dividend date of this dividend was Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.90%. Johnson & Johnson’s dividend payout ratio is 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Is it Safe to Invest in Commodities?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.